Banner

Article

Linagliptin cardiovascular safety profile appears superior to glimepiride

Cardiovascular events were fewer in patients with type 2 diabetes randomized to 2 years of the DPP-4 inhibitor linagliptin compared with glimepiride as add-on therapy to metformin, according to data from a phase III study.

Newsletter

Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.

Subscribe Now!
Related Videos
A new chapter in student loans: Video explainer © Nadzeya - stock.adobe.com
Related Content
medical coding cpt code illustration: © VectorMine - stock.adobe.com
September 12th 2025

RPM, AI, hearing devices get CPT code updates for 2026

Off the Chart: A Business of Medicine Podcast - Ep. 83: Community, leadership and mental health in medicine, with AOA President Robert Piccinini, D.O.
September 12th 2025

Leadership and mental health in medicine, with AOA President Robert Piccinini, D.O.

Morning Medical Update © everythingpossible - stock.adobe.com
September 12th 2025

“Kissing bug” disease an endemic in the U.S.; National Academies proposals to improve breastfeeding rates; TB fight at risk amid funding cuts – Morning Medical Update

Off the Chart: A Business of Medicine Podcast - Ep. 82: Practice leadership, with Kem Tolliver, FACMPE, CPC, CMOM, of Medical Revenue Cycle Specialists
September 12th 2025

Practice leadership with Kem Tolliver of Medical Revenue Cycle Specialists

independent physician doctor: © Khunatorn - stock.adobe.com
September 12th 2025

Independent physician practices deliver lower-cost care: Study highlights need for site-neutral payment reform

The newest Apple Watch will flag possible hypertension, pending FDA clearance © Apple Inc.
September 12th 2025

The newest Apple Watch will flag possible hypertension, pending FDA clearance

© 2025 MJH Life Sciences

All rights reserved.